HomeNSIS-B • CPH
Novozymes A/S
kr 476.80
Sep 27, 9:05:44 PM GMT+2 · DKK · CPH · Disclaimer
StockGLeaf logoClimate leaderDK listed security
Previous close
kr 475.90
Day range
kr 474.70 - kr 480.40
Year range
kr 375.90 - kr 480.40
Market cap
192.02B DKK
Avg Volume
557.47K
P/E ratio
-
Dividend yield
-
Primary exchange
CPH
CDP Climate Change Score
A
Market news
Financials
Income Statement
Revenue
Net income
(EUR)Jun 2024Y/Y change
Revenue
915.85M61.70%
Operating expense
271.75M52.62%
Net income
31.95M-60.72%
Net profit margin
3.49-75.70%
Earnings per share
——
EBITDA
150.94M-16.50%
Effective tax rate
29.00%—
Total assets
Total liabilities
(EUR)Jun 2024Y/Y change
Cash and short-term investments
260.80M85.35%
Total assets
15.25B302.43%
Total liabilities
4.25B119.23%
Total equity
11.00B—
Shares outstanding
277.90M—
Price to book
12.02—
Return on assets
1.83%—
Return on capital
2.15%—
Net change in cash
(EUR)Jun 2024Y/Y change
Net income
31.95M-60.72%
Cash from operations
264.05M74.01%
Cash from investing
-27.45M70.98%
Cash from financing
-186.70M-205.10%
Net change in cash
55.55M902.56%
Free cash flow
-17.57M68.87%
About
Novozymes A/S was a global biotechnology company headquartered in Bagsværd, outside of Copenhagen, Denmark. The company's focus was the research, development and production of industrial enzymes, microorganisms, and biopharmaceutical ingredients. The company merged with Chr. Hansen to form Novonesis in January 2024. Prior to the merger, the company had operations around the world, including in China, India, Brazil, Argentina, United Kingdom, the United States, and Canada. Class B shares of its stock were listed on the NASDAQ OMX Nordic exchange. On 12 December 2023, it was announced that Nozozymes and Danish bioscience company Chr. Hansen had obtained regulatory approval for a merger, and on the following day, the name of the combined company was revealed as Novonesis. Wikipedia
Founded
2000
Employees
10,452
Search
Clear search
Close search
Google apps
Main menu